Merz Pharmaceuticals

FRANKFURT, Germany, June 8, 2011 - - Data Show XEOMIN Improves Symptoms Of Cervical Dystonia And Blepharospasm When Administered Across And Beyond The Standard Dosing Regimen Merz Pharmaceuticals today announced that new data on Xeomin(R) (incobotulinumtoxinA), a botulinum toxin type A free from accessory (complexing) proteins, will be presented at the Movement Disorder Society's (MDS) 15th International Congress of Parkinson's Disease and Movement Disorders in Toronto, Canada.